Belt and Road Summit 2025- Deal-making

10–16 Sept 2025 | China (Hong Kong)

ProjectUpdated on 3 September 2025

Trophy Life Technology

Daisy Tan

Business Development Officer at InnoHK Centre for Translational Stem Cell Biology

Hong Kong, China (Hong Kong)

About

Trophy Life Tech accelerates antiviral innovation through its proprietary placenta-like stem cell platform (TSC-STB), enabling rapid and accurate discovery of novel antiviral candidates and development of effective antiviral drugs and health products.

Why Trophy Life

•Proprietary stem cell platform facilitates fast, cost-effective, and highly sensitive antiviral drug screening

•Supports development of broad-spectrum antiviral drugs, supplements, and healthcare products tailored to diverse viral threats

•Unique placenta-like stem cell model mimics human viral infection dynamics, enabling precise efficacy and safety testing

Our advanced platform empowers pharma and biotech partners to overcome traditional drug discovery challenges with scalable, validated cellular models.

Project Location

  • China (Hong Kong)

Project Format

  • Public-Private Partnership Project

ESG (Environmental, Social, and Governance)

  • No

Project Stage

  • Project Planning

Main Project Sector

  • Technology

Technology

  • Bio-Tech
  • Health Technology

Total Project Value

  • 500,000 USD or Below

Investment Capital Required

  • 1,000,001 to 2,500,000 USD

Interested Format of Cooperation

  • Joint Venture
  • Open for Negotiation
  • Requisition of Service
  • R&D Cooperation

Preferred Financing Model

  • Open for negotiation

Previous Funding Stage

  • Seed & Pre-Series

Main Service(s) Required

  • Financial Services
  • Professional Services

Organisation

InnoHK Centre for Translational Stem Cell Biology

Hong Kong Science and Technology Park, China (Hong Kong)

Similar opportunities

  • Project

    Estelle Biovita

    • No
    • None
    • Bio-Tech
    • Technology
    • Joint Venture
    • R&D Cooperation
    • Project Planning
    • Health Technology
    • Financial Services
    • 500,000 USD or Below
    • Open for Negotiation
    • Open for negotiation
    • Professional Services
    • 1,000,001 to 2,500,000 USD
    • Public-Private Partnership Project

    Daisy Tan

    Business Development Officer at InnoHK Centre for Translational Stem Cell Biology

    Hong Kong, China (Hong Kong)

  • Project

    Single Cell Drug Screening AI Platform

    • Yes
    • None
    • Equity
    • Bio-Tech
    • Technology
    • Private Project
    • R&D Cooperation
    • Open for negotiation
    • Professional Services
    • Minority Shareholdings
    • 2,500,001 to 5,000,000 USD
    • 1,000,001 to 2,500,000 USD
    • Feasibility Study Completed
    • Public–private partnership / Concession

    Marco Suen

    Founder & CEO at Provectus Therapeutics Limited

    Hong Kong, China (Hong Kong)

  • Project

    Genome Technology

    • No
    • Bio-Tech
    • Operations
    • Technology
    • Private Project
    • Seed & Pre-Series
    • Medical Technology
    • Financial Services
    • Open for Negotiation
    • Open for negotiation
    • Professional Services
    • 500,001 to 1,000,000 USD
    • 1,000,001 to 2,500,000 USD

    Daisy Tan

    Business Development Officer at InnoHK Centre for Translational Stem Cell Biology

    Hong Kong, China (Hong Kong)